Excellent response to levetiracetam in epilepsy with Wolf-Hirschhorn syndrome
- 277 Downloads
Wolf-Hirschhorn syndrome (WHS) is a rare genetic disorder caused by subtelomeric deletion of a segment of the short arm (p) of chromosome 4. Epilepsy constitutes a major medical challenge especially during the first years of life and occurs in 50–100 % of patients with WHS The conventional antiepileptic drugs such as carbamazepine, phenobarbitale, and valproic acid have been tried and are rarely effective in these patients [1, 2]. Levetiracetam is a new line antiepileptic drug indicated for partial seizures with or without secondary generalization.
KeywordsIntellectual Disability Levetiracetam Translocation Carrier Phenobarbitale Treatment Conventional Anticonvulsant Drug
Compliance with ethical standards
Conflict of interest
The authors declare that thay have no conflict of interest.
- 6.Klitgaard H, Pitkanen A (2003) Antiepileptogenesis, neuroprotection, and disease modification in the treatment of epilepsy: focus on levetiracetam. Epileptic Disord 5:9–16Google Scholar